Can Mounjaro Make You Anxious?

What clinical trial data tell us about tirzepatide and anxiety

The SURMOUNT programme (the phase 3 trials that underpinned Mounjaro's UK licence) enrolled thousands of adults with obesity over 72 weeks. Across that dataset, anxiety was not identified as a common adverse event; the dominant side-effect signals were gastrointestinal: nausea, loose stools, constipation, and indigestion, typically peaking after a dose step and settling within a week or two. The NHS medicines page for tirzepatide reflects the same picture: mood-related effects do not feature in the 'common' or 'very common' categories.

That matters, because there was a period when online discussion conflated GLP-1 medicines broadly with mood changes, partly because semaglutide research touched on appetite-regulating brain circuits, prompting speculation about psychological effects. The evidence for tirzepatide specifically does not support anxiety as a predictable outcome. People sometimes also wonder whether Mounjaro works like an SGLT2 inhibitor, which is a separate class of medicine with its own distinct mechanism and side-effect profile. A misconception worth letting go: Mounjaro does not appear to act on the anxiety pathways in the brain the way a stimulant medication might.

None of this means your experience is wrong if you do feel unsettled early on. It means the mechanism is almost certainly indirect, which makes it easier to identify and address. Read about how tirzepatide works as a dual GIP and GLP-1 receptor agonist if you want a fuller picture of its mechanism.

Why some people feel jittery or anxious in the first few weeks

Several indirect effects can produce feelings that resemble anxiety, even when the medicine itself is not acting on mood.

The most common is nausea-related unease. When gastric emptying slows and appetite drops sharply, some people feel physically uncomfortable in a way that triggers a low-grade state of alertness. That physical tension (heart rate slightly up, stomach unsettled) can read as anxiety, even though the cause is digestive. It typically resolves as the body adjusts, often within two weeks of a dose step.

A second factor is blood-glucose fluctuation. In people without diabetes this is usually mild, but if meals become very small or are skipped because appetite has vanished, blood sugar can dip enough to produce shakiness, a racing heart, and a sense of unease. Eating regularly, even in smaller amounts, usually prevents this. If you notice dizziness or lightheadedness alongside the jitteriness, low blood sugar is worth considering.

A third possibility is simply the psychological adjustment to a significant change in your relationship with food. Appetite suppression can feel disorienting at first. Hunger cues that used to structure your day go quiet; some people find that unsettling. That is a normal psychological response to a real physiological shift, not a side effect of the medicine itself.

When to raise it with your prescriber, and what not to ignore

Transient unease that tracks with nausea and fades within a fortnight is worth noting but not usually alarming. The scenarios that warrant prompt contact are different.

If anxiety feels persistent, severe, or out of proportion to anything you can attribute to nausea or eating patterns, tell your prescriber. If you notice low mood deepening alongside it, that matters more. The MHRA asks patients and clinicians to remain alert to psychological symptoms with any medicine that acts on appetite-regulating hormones, even where the evidence of a causal link remains limited. Our clinical team reviews these questions at every stage of treatment, not only at the start.

Any thoughts of self-harm or suicide require urgent help: contact your GP, call 111, or go to A&E. Do not wait for a scheduled prescription review. You can also report any suspected side effects directly through the MHRA Yellow Card scheme, which is open to patients as well as clinicians.

People with a diagnosed anxiety disorder, or who are taking medication for mood, should discuss this openly during their consultation. The prescriber may still consider treatment appropriate, but they need the full picture. You can explore what the consultation covers before you start.

Putting it in context alongside other reported side effects

Mounjaro has a well-characterised side-effect profile. The effects most consistently seen (nausea, fatigue, occasional headache, changes in bowel habit) are real and worth preparing for. Some people also ask about heat sensitivity; there is separate guidance on that if it is relevant to you.

The point about anxiety specifically is that it sits in a different category: not a confirmed direct effect, but something a small number of people experience indirectly, and something that is easy to misattribute if you are not expecting it. If you have ever found yourself questioning whether the medicine is doing anything at all, there is a page that addresses whether Mounjaro's effects could simply be a placebo response, which sets out what the clinical evidence actually shows. Knowing the likely mechanism (nausea, appetite disruption, blood-sugar shifts) means you can respond to it practically rather than worrying that the medicine is doing something it is not supposed to.

The full Mounjaro overview covers the broader evidence base, eligibility criteria, and how private treatment works in the UK. If cost is a factor in your thinking, the weight-loss treatment page sets out what is included in a single transparent price. And if anxiety about starting treatment (rather than a side effect of it) is what is holding you back, speaking to a prescriber directly is usually the most useful step.